# HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

> **NCT06824155** · EARLY_PHASE1 · RECRUITING · sponsor: **Radiopharm Theranostics, Ltd** · enrollment: 30 (estimated)

## Conditions studied

- HER2 Gene Mutation
- Advanced Solid Tumors

## Interventions

- **DRUG:** 177Lu-RAD202

## Key facts

- **NCT ID:** NCT06824155
- **Lead sponsor:** Radiopharm Theranostics, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-12
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06824155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06824155, "HEAT Trial (HER2 Antibody Therapy With Lutetium-177)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06824155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*